title: Influence of montelukast on cisplatin-induced experimental acute renal failure.
abstract: OBJECTIVE
  To investigate the influence of Montelukast (MK) in acute renal failure (ARF) experimentally induced by cisplatin (CIS).
  
  
  METHODS
  The experiment was carried out in male Wistar rats (280-320g), divided into 4 groups of 12 animals each, treated as follows: Group I (Control); Group II (CIS): CIS, 5 mg/kbw, single dose, i.p.; Group III (CISMK): CIS, 5 mg/kbw, single dose, i.p and MK 2 mg/kbw, p.o., 10 days; Group IV (MK): MK 2 mg/kbw, p.o., 10 days. Blood and urine (24 h) samples were taken before the start of experiment (Io) and at 3, 7, 10 and 14 days after CIS administration. The following were determined: urea, creatinine, Ca, Mg serum levels and creatinine, proteins, Ca and Mg urinary levels. For histological evaluation, 3 rats of each group were sacrificed at 3, 7, 10 and 14 days. The severity of histopathological changes was evaluated using scores on a 1-4 point scale.
  
  
  RESULTS
  Both in CIS and CISMK group, serum levels of urea and creatinine and urinary protein levels were significantly higher compared with Io values and control group at 3 and 7 days, (p < 0.01 and p < 0.05, respectively). Urinary creatinine levels were significantly decreased at 3 and 7 days, (p < 0.01) and (p < 0.05) in CIS and CISMK group compared to Io and control group. The degree of severity of histopathological changes was similar in CIS and CISMK group.
  
  
  CONCLUSIONS
  The obtained results showed that MK at a dose of 2 mg/kbw had no protective effect in CIS-induced experimental acute renal failure.
authors.forename: Oana
authors.initials: O
authors.lastname: Teslariu
authors.forename: M
authors.initials: M
authors.lastname: Nechifor
authors.forename: P
authors.initials: P
authors.lastname: Plămădeală
authors.forename: Ingrith Crenguţa
authors.initials: IC
authors.lastname: Miron
mesh_terms: D000085:Acetates / Q000494:pharmacology*; D058186:Acute Kidney Injury / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy* / Q000652:urine; D000818:Animals; D015415:Biomarkers / Q000097:blood; D001798:Blood Proteins; D001806:Blood Urea Nitrogen; D002118:Calcium / Q000652:urine; D002945:Cisplatin / Q000633:toxicity; D003404:Creatinine / Q000097:blood; D003521:Cyclopropanes; D004195:Disease Models, Animal; D020024:Leukotriene Antagonists / Q000494:pharmacology*; D008274:Magnesium / Q000652:urine; D008297:Male; D011804:Quinolines / Q000494:pharmacology*; D017208:Rats, Wistar; D013440:Sulfides; D017211:Treatment Failure
chemical_list: D000085:Acetates; D015415:Biomarkers; D001798:Blood Proteins; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; D003404:Creatinine; D008274:Magnesium; C093875:montelukast; D002945:Cisplatin; D002118:Calcium